MedCity News November 21, 2024
Frank Vinluan

Kura Oncology already had a broad development plan for ziftomenib in leukemias, but the agreement with Kyowa Kirin provides the cash to execute it and a partner to commercialize the drug globally. Ziftomenib is in the same class of medicines as Syndax Pharmaceuticals’ Revuforj, which won FDA approval last week.

The FDA recently approved the first drug in a new class of leukemia medicines. Kura Oncology’s endeavor to follow that newly blazed regulatory trail is now infused with $330 million from a collaboration agreement with Kyowa Kirin.

The Kura drug, ziftomenib, has completed a Phase 2 test designed to support a new drug application that the companies expect will be submitted to the FDA in 2025 seeking approval as a...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma, Pharma / Biotech, Trends
Why Walgreens Is Reportedly Considering a Private Equity Buyer
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
Why 2025 Could Be A Good Reimbursement Year For CVS And Walgreens
PBM reform dropped in Congress' funding package
2025 and Beyond: Key Trends to Watch in Pharmacy

Share This Article